The ARCADIA Study -- A medication study for prevention of recurrent ischemic stroke
Official Title
AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke (ARCADIA)
Purpose
The purpose of this research study is to compare the effects (good and bad) of apixaban with the effects (good and bad) of aspirin in patients with unexplained strokes and atrial cardiopathy to see which is better at prevention of future strokes.
Could this study be right for you?
- You are at least 45 years old
- Clinical diagnosis of ischemic stroke* of unknown cause (ESUS or cryptogenic) in the last 120 days
- Underwent an echocardiogram as part of your stroke work up
- No history of atrial fibrillation (irregular heartbeat)
- No known allergy or intolerance to aspirin or apixaban
*An “ischemic” stroke is an injury to the brain caused by a blocked blood vessel supplying the brain.